Cannabis stocks proxy Horizons Marijuana Life Sciences Index ETF (TSE:HMMJ) officially entered bear market conditions this morning. Amazingly, it took just five days to do so after attaining a record closing high on October 15th—two days before the advent of Canadian cannabis legalization. The extreme weakness is reminiscent of January’s harrowing dual declines, which sent prices spiraling ↓21.82 % and ↓37.08%, respectively, on a peak-to-trough basis. Even as the industry rapidly matures, sector volatility remains rampant.
For a few fleeting moments this morning, it looked as if cannabis stocks had found its sea legs. Sector captain, Canopy Growth Corp., tested and passed the key $46.10-46.50 levels, printing to as high of $47.83 within the first ten minutes of trade. With overall sector technicals looking atrocious, market participants again looked for Canopy to stem the selling tide, as it has on so many prior occasions. Constructive close or not, it wasn’t to be.
For the third consecutive session, the market sold heavily into the fleeting morning strength, taking out $46.10-46.50 support and forging 5-week lows with ease. More representative of the onslaught were prices of HMMJ, reaching official bear market status by printing at $20.84 at 10:20 am EST. After some very weak consolidation, prices again surged lower. At publishing time, HMMJ declined $2.45 to $20.48 (↓10.68%).
The extreme technical damage hitting individual names is quite pervasive, and not limited to Canadian licensed producers. U.S. cannabis stocks, as defined by the United States Marijuana Index, are lower by almost ten percent. Practically everyone is suffering in a congruent manner, with no discrimination between small, mid and large caps.
(As of 12:55 pm, EST)
|Namaste Technologies Inc.||1.86||-0.36||-16.22%||6,877,510|
|The Green Organic Dutchman Holdings||4.19||-0.74||-15.01%||2,358,070|
|Emerald Health Therapeutics Inc.||3.34||-0.57||-14.58%||1,146,022|
|The Supreme Cannabis Company Inc.||1.55||-0.26||-14.36%||3,087,057|
|Newstrike Brands Ltd.||0.54||-0.09||-14.29%||3,530,103|
|Aurora Cannabis Inc.||11.44||-1.57||-12.07%||40,527,333|
|Auxly Cannabis Group Inc.||1.03||-0.14||-11.97%||5,130,826|
|Isodiol International Inc.||2.65||-0.36||-11.96%||186,341|
(As of 1:19 pm, EST)
|Cannex Capital Holdings Inc.||0.61||-0.1||-14.08%||230,742|
|MedMen Enterprises Inc.||7.41||-1.09||-12.82%||2,636,863|
|MPX Bioceutical Corporation||1.02||-0.12||-10.53%||2,711,825|
|CV Sciences Inc.||5.07||-0.53||-9.46%||1,113,262|
|Liberty Health Sciences Inc.||1.3||-0.13||-9.09%||1,433,491|
|Golden Leaf Holdings Ltd.||0.2||-0.02||-9.09%||2,269,934|
|Charlottes Web Holdings Inc.||15.35||-1.43||-8.52%||213,598|
For veteran cannabis investors, this bearish impulse will come as no surprise. Canopy Growth has endured at least eight such similar impulses—defined as price drops of at least 20% or more within a two week span—since November 2016. Every single occasion provided a gift for long term investors to add to positions. Will it be the same this time? Although investors must make their own determinations, it’s hard to envision any deterioration in Canopy’s long term bull outlook with U.S. and international expansion still in its nascent stage. The company is about to close it’s $5 billion direct-equity stake deal with Constellation Brands Inc., giving it the firepower to branch out in ways most LP’s can only dream of.
The next notable levels on HMMJ and Canopy Growth (CGC) are $20.27 and $40.68, respectively. We shall provide further technical updates once a more solid sector bull case has developed—beyond a couple dabs of sunlight.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.